Bellevue Group AG and its wholly owned subsidiary Bellevue Asset Management AG, both organized in Switzerland, report their beneficial ownership in Jade Biosciences, Inc. common stock in this amended filing. The securities class is common stock of Jade Biosciences, Inc., CUSIP 008064206.
The reporting persons state beneficial ownership of 3,057,996 shares of common stock, representing 5.0% of the class. They report 0 shares with sole voting or dispositive power and 3,057,996 shares with shared voting and shared dispositive power. The percentage is based on 60,845,967 shares of common stock outstanding as of June 5, 2026, after an equity offering by Jade Biosciences, as referenced in the company’s prospectus supplement filed June 4, 2026 and press release dated June 5, 2026. The statement is filed jointly by Bellevue and Bellevue Asset Management AG as a parent holding company and its subsidiary.
Positive
None.
Negative
None.
Key Figures
Beneficial ownership shares:3,057,996 sharesPercent of class owned:5.0%Shares outstanding baseline:60,845,967 shares+3 more
6 metrics
Beneficial ownership shares3,057,996 sharesShares of Jade Biosciences common stock beneficially owned by Bellevue and Bellevue Asset Management
Percent of class owned5.0%Ownership percentage of Jade Biosciences common stock reported by the filing persons
Shares outstanding baseline60,845,967 sharesJade Biosciences common shares outstanding as of June 5, 2026 after equity offering
Shared voting power3,057,996 sharesNumber of shares over which the reporting persons have shared voting power
Sole voting power0 sharesNumber of shares over which the reporting persons have sole voting power
Shared dispositive power3,057,996 sharesNumber of shares over which the reporting persons have shared dispositive power
"The percentages of beneficial ownership contained herein are based on 60,845,967 shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting powerfinancial
"Shared Voting Power 3,057,996.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerfinancial
"Shared Dispositive Power 3,057,996.00"
parent holding companyfinancial
"This statement is filed jointly by Bellevue and BAM AG. BAM AG is a wholly-owned subsidiary"
FAQ
What percentage of Jade Biosciences (JBIO) does Bellevue Group report owning?
Bellevue Group AG and its subsidiary report 5.0% beneficial ownership of Jade Biosciences common stock. This is based on 60,845,967 shares outstanding as of June 5, 2026, after an equity offering by Jade Biosciences.
How many Jade Biosciences (JBIO) shares does Bellevue Group beneficially own?
Bellevue Group and Bellevue Asset Management AG report beneficial ownership of 3,057,996 Jade Biosciences common shares. All these shares are reported with shared voting and shared dispositive power, and no shares with sole voting or dispositive power.
What share count did Bellevue use to calculate its 5.0% stake in JBIO?
The 5.0% figure is calculated using 60,845,967 Jade Biosciences common shares outstanding as of June 5, 2026. This outstanding share number reflects the closing of an equity offering referenced in the company’s prospectus supplement and press release.
Who are the reporting persons in this Jade Biosciences (JBIO) Schedule 13G/A?
The reporting persons are Bellevue Group AG and its wholly owned subsidiary Bellevue Asset Management AG, both organized in Switzerland. They file the ownership statement jointly as a parent holding company and its asset management subsidiary.
Does Bellevue Group have sole or shared voting power over its JBIO shares?
Bellevue reports 0 shares with sole voting power and 3,057,996 shares with shared voting power. The same numbers apply to dispositive power, indicating all reported Jade Biosciences shares are jointly controlled for voting and disposition.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Jade Biosciences, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
008064206
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
008064206
1
Names of Reporting Persons
Bellevue Group AG
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
SWITZERLAND
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,057,996.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,057,996.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,057,996.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
HC, CO
Comment for Type of Reporting Person: The percentages of beneficial ownership contained herein are based on 60,845,967 shares of Common Stock outstanding as of June 5, 2026 (after giving effect to the closing of an equity offering by the Issuer on such date), as reported by the Issuer in its Prospectus Supplement filed with the SEC on June 4, 2026 and its Press Release issued on June 5, 2026.
SCHEDULE 13G
CUSIP Number(s):
008064206
1
Names of Reporting Persons
Bellevue Asset Management AG
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
SWITZERLAND
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,057,996.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,057,996.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,057,996.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
CO
Comment for Type of Reporting Person: The percentages of beneficial ownership contained herein are based on 60,845,967 shares of Common Stock outstanding as of June 5, 2026 (after giving effect to the closing of an equity offering by the Issuer on such date), as reported by the Issuer in its Prospectus Supplement filed with the SEC on June 4, 2026 and its Press Release issued on June 5, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Jade Biosciences, Inc.
(b)
Address of issuer's principal executive offices:
221 CRESCENT ST. BUILDING 23, SUITE 105 WALTHAM, MA, 02453
Item 2.
(a)
Name of person filing:
Bellevue Group AG ("Bellevue") on behalf of its wholly-owned subsidiary, Bellevue Asset Management AG ("BAM AG")
(b)
Address or principal business office or, if none, residence:
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
3,057,996
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
This statement is filed jointly by Bellevue and BAM AG. BAM AG is a wholly-owned subsidiary of Bellevue.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
